Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03431233
Other study ID # H-1705-091-855
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date June 1, 2019

Study information

Verified date August 2019
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to explore premeal protein-enriched bar effect in food intake in healthy subjects.


Description:

Twenty healthy subjects will be recruited. Every subject will be randomized in 6 groups and studied on 3 separate days in random order with 1 week intervals. These participants will consume protein enriched bar, commercial cereal bar, or water followed by a standardized diet (gimbap). For study outcomes, food intake, appetite and satiety (visual analog scale), plasma glucose, and satiety related hormone will be measured. Blood sampling will be done before 15 min of breakeast, at the moment of start of breakfast (0 min), and then 30, 60, 90, 120 min. Plasma glucose levels, total/active GLP-1, ghrelin, total PYY will be measured.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 1, 2019
Est. primary completion date June 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 80 Years
Eligibility - Inclusion Criteria:

- BMI 18.5~35 kg/m2

- Never diagnosed by diabetes

- Fasting plasma glucose <=100mg/dl and HbA1c <6.0%

- Exclusion Criteria:

- Those who diagnosed by Type 1 or Type 2 diabetes

- Allergy to wheat, flour, nuts, milk

- Pregnancy/lactation

- AST or ALT >2.5 times of upper normal reference range

- eGFR <30 mL/min/1.73m2

- Hb <10g/dl

- History of GI surgery (except hemorrhoidectomy, appendectomy)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Protein-enriched bar, commercial cereal bar, or water
Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Food intake grams and caloric intake of standardized gimbap 120min
Secondary Appetite (visual analogue scale : score 1 to 10) (1: I am not hungry at all, 10: I have never been more hungry) 120min
Secondary Satiety (visual analogue scale : score 1 to 10) 120min
Secondary plasma glucose (mmol/L) plasma level of glucose -15min, 0(breakfast), 30, 60, 90, 120 min
Secondary plasma active/total GLP-1 (pmol/L) plasma level of active/total GLP-1 -15min, 0(breakfast), 30, 60, 90, 120 min
Secondary plasma active ghrelin (ng/ml) plasma level of active ghrelin -15min, 0(breakfast), 30, 60, 90, 120 min
Secondary plasma total peptide YY (pg/ml) plasma level of peptide YY -15min, 0(breakfast), 30, 60, 90, 120 min
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1